Adjuvant TG4050 was well tolerated and generated long-lasting neoantigen-specific T-cell responses in resected HPV-negative HNSCC.
News|Articles|September 26, 2025
AI in oncology: Fundamentals to full integration into your practice
Explore Tempus' latest advancements in artificial intelligence and how it is being applied in real-world oncology settings with Dr. Sanjay Juneja of Tempus and Dr. Debra Patt of Texas Oncology.
Advertisement
Advertisement
Related to this article
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in September 2026 spanning tumor types.
The FDA approved tucatinib plus trastuzumab and pertuzumab as maintenance for advanced HER2-positive breast cancer after induction.
The c-Met–directed ADC was designated for EGFR wild-type nonsquamous NSCLC after platinum chemotherapy and anti–PD-(L)1 therapy.
Dana-Farber’s Xin Gu, PhD, and Nicholas Polizzi, PhD, received NIH New Innovator Awards for high-risk, high-reward research.
The c-Met–directed ADC-based combination was designated for mCRC previously treated with fluoropyrimidine, irinotecan, oxaliplatin, and anti-VEGF therapy.
Pooled data from 3 randomized trials showed ropeginterferon alfa-2b improved responses vs phlebotomy alone but not vs hydroxyurea in polycythemia vera.
Experts break down key multiple myeloma data and trends from the 23rd Annual IMS Meeting.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Tucatinib Plus Trastuzumab/Pertuzumab as First-Line Maintenance in Advanced HER2+ Breast Cancer
2
FDA Grants Breakthrough Therapy Designation to Temab-A in Previously Treated c-Met–Expressing Nonsquamous NSCLC
3
FDA Grants Breakthrough Therapy Designation to Telisotuzumab Adizutecan Plus Bevacizumab in Refractory mCRC
4
September Roundup of FDA Approvals in Oncology: 8 Decisions to Know
5